CURE announced a licensing agreement with Vanguard, giving Vanguard the right to practice CURE’s patented cannabis extraction methods.
CURE Pharmaceutical (OTC:CURR) announced a licensing and collaboration agreement with Vanguard Scientific Systems, giving Vanguard the right to practice CURE’s patented cannabis extraction methods.
As quoted in the press release:
“This license agreement gives operational freedom to a leader in the supercritical fluid extraction industry who is committed to pharma-grade standards continuing our powered by Cure licensing strategy,” said Rob Davidson, CEO of CURE Pharmaceutical. “Building on this license, we will collaborate with Vanguard Scientific experts to expand the licensed patent estate to cover the most recent advances in the field.”
CURE has granted Vanguard rights to its portfolio of issued and pending process and composition patents for isolating cannabinoids using an advanced supercritical fluid extraction technology utilizing carbon dioxide as the solvent. While the patents cover the incorporation of cannabis extracts into multiple dosage forms, CURE has reserved all rights to applying these methods in oral thin film.